Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial

F. Boccardo, A. Rubagotti, D. Amoroso, P. Sismondi, F. Genta, I. Nenci, A. Piffanelli, A. Farris, L. Castagnetta, A. Traina, M. Cappellini, P. Pacini, M. Sassi, P. Malacarne, D. Donati, G. Mustacchi, L. Galletto, G. Schieppati, E. Villa, A. BolognesiL. Gallo, participants in the Grocta other participants in the Grocta

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences